PRELID2 and nonpapillary renal cell carcinoma: On one hand, it enhances the predictability of survival outcomes in ccRCC patients; on the other hand, the six nc-MTGs (BID, FKBP10, PRELID2, FDXR, POLG2, and ACADM) within this feature can also assess the immune status and immune checkpoints of ccRCC patients.